证券记录 · 已归档季度
BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
19被追踪持有人
0Δ持有人
57.19M持有股份
$4.02B报告持仓市值
+2新建仓位
−2清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +6.3% · 净新建仓位 0.0% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.42M | $84.45M | n/a | −2 |
| Q2 2026 | 135 | +4 | 146.70M | $8.39B | +11 | −8 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | n/a |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | n/a | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | n/a | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | n/a |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | n/a | 53.80M | $4.43B | n/a | n/a |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 18.87M | +0.4% | $1.33B | 1.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Dodge & Cox ✦ | 13.90M | -0.2% | $976.91M | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 3 | Viking Global Investors ✦ | 9.75M | +38.1% | $685.56M | 2.5% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (被动) | 3.53M | -2.4% | $248.37M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Elliott Investment Management ✦ | 3.50M | 0.0% | $246.04M | 2.4% | Held | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (被动) | 3.26M | +1.9% | $228.63M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.20M | +115.9% | $84.66M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 663.55K | -32.5% | $46.64M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 642.68K | -42.5% | $45.17M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 598.50K | +980.9% | $42.07M | 0.1% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 418.87K | +260.5% | $29.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 299.53K | -12.0% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 197.72K | 新增 | $13.90M | 0.0% | New | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 163.35K | -39.1% | $11.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Bridgewater Associates ✦ | 142.31K | +306.8% | $10.00M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 23.39K | 新增 | $1.64M | 0.0% | New | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 13.55K | +0.9% | $952,148 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Wellington Management ✦ | 7.06K | +2.0% | $496,177 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 19 | GAMCO Investors ✦ | 6.57K | +23.5% | $461,454 | 0.0% | ▲ Add | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $13.90M | 0.0% |
| Gotham Asset Management | $1.64M | 0.0% |
已清仓
| Soros Fund Management | $12.85M | 曾为 0.4% |
| Marshall Wace | $3.52M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 549 持有人, 183.01M 股份, $10.09B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 02
Davis George Eric
Officer · 17.56K 股 · $1.16M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据